Medical, News Headlines

Concert Pharmaceuticals Plans CTP-543 Phase 3 trials in Alopecia Areata

Concert Pharmaceuticals Plans CTP-543 Phase 3 trials in Alopecia Areata

Concert Pharmaceuticals is planning to proceed with its Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. “Our intent is to initiate the Phase 3 program of CTP-543 in the fourth quarter of 2020, pending COVID-19 to bring an important new treatment option to people living with this life-altering autoimmune disease.” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. Alopecia areata may affect up to 650,000 Americans at any given time. The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

8 thoughts on “Concert Pharmaceuticals Plans CTP-543 Phase 3 trials in Alopecia Areata”

  1. Shawn Mathews says:

    FDA will have to continue with this research

  2. Shawn Mathews says:

    FDA will have to continue with this research

  3. Hodgins Hawkin says:

    good step

  4. Angela Markens says:

    Kudos

  5. Andrew John says:

    this work is good for people who are suffering from this kind of disease

  6. Mike Ethans says:

    Hope will hear the good news in forth quarter.

  7. Hodgins Hawkin says:

    Keep it up! good initiative

  8. Niki Halms says:

    Bravo!